Effectiveness of very low-volume preparation for colonoscopy: A prospective, multicenter observational study.


Journal

World journal of gastroenterology
ISSN: 2219-2840
Titre abrégé: World J Gastroenterol
Pays: United States
ID NLM: 100883448

Informations de publication

Date de publication:
28 Apr 2020
Historique:
received: 10 01 2020
revised: 26 03 2020
accepted: 21 04 2020
entrez: 12 5 2020
pubmed: 12 5 2020
medline: 9 2 2021
Statut: ppublish

Résumé

The effectiveness of colonoscopy strictly depends on adequate bowel cleansing. Recently, a 1 L polyethylene glycol plus ascorbate (PEG-ASC) solution (Plenvu; Norgine, Harefield, United Kingdom) has been introduced on the evidence of three phase-3 randomized controlled trials, but it had never been tested in the real-life. To assess the effectiveness and tolerability of the 1 L preparation compared to 4 L and 2 L- PEG solutions in a real-life setting. All patients undergoing a screening or diagnostic colonoscopy after a 4, 2 or 1 L PEG preparation, were consecutively enrolled in 5 Italian centers from September 2018 to February 2019. The primary endpoints of the study were the assessment of bowel cleansing success and high-quality cleansing of the right colon. The secondary endpoints were the evaluation of tolerability, adherence and safety of the different bowel preparations. Bowel cleansing was assessed through the Boston Bowel Preparation Scale. Adherence was defined as consumption of at least 75% of each dose, while tolerability was evaluated through a semi-quantitative scale. Safety was systematically monitored through adverse events reporting. Overall, 1289 met the inclusion criteria and were enrolled in the study. Of these, 490 patients performed a 4 L-PEG preparation (Selgesse This study supports the effectiveness and tolerability of 1 L PEG-ASC, also showing it is an independent predictor of overall cleansing success, high-quality cleansing of the right colon and of tolerability.

Sections du résumé

BACKGROUND BACKGROUND
The effectiveness of colonoscopy strictly depends on adequate bowel cleansing. Recently, a 1 L polyethylene glycol plus ascorbate (PEG-ASC) solution (Plenvu; Norgine, Harefield, United Kingdom) has been introduced on the evidence of three phase-3 randomized controlled trials, but it had never been tested in the real-life.
AIM OBJECTIVE
To assess the effectiveness and tolerability of the 1 L preparation compared to 4 L and 2 L- PEG solutions in a real-life setting.
METHODS METHODS
All patients undergoing a screening or diagnostic colonoscopy after a 4, 2 or 1 L PEG preparation, were consecutively enrolled in 5 Italian centers from September 2018 to February 2019. The primary endpoints of the study were the assessment of bowel cleansing success and high-quality cleansing of the right colon. The secondary endpoints were the evaluation of tolerability, adherence and safety of the different bowel preparations. Bowel cleansing was assessed through the Boston Bowel Preparation Scale. Adherence was defined as consumption of at least 75% of each dose, while tolerability was evaluated through a semi-quantitative scale. Safety was systematically monitored through adverse events reporting.
RESULTS RESULTS
Overall, 1289 met the inclusion criteria and were enrolled in the study. Of these, 490 patients performed a 4 L-PEG preparation (Selgesse
CONCLUSION CONCLUSIONS
This study supports the effectiveness and tolerability of 1 L PEG-ASC, also showing it is an independent predictor of overall cleansing success, high-quality cleansing of the right colon and of tolerability.

Identifiants

pubmed: 32390705
doi: 10.3748/wjg.v26.i16.1950
pmc: PMC7201146
doi:

Substances chimiques

Cathartics 0
Polyethylene Glycols 3WJQ0SDW1A
Ascorbic Acid PQ6CK8PD0R

Types de publication

Journal Article Multicenter Study Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

1950-1961

Informations de copyright

©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.

Déclaration de conflit d'intérêts

Conflict-of-interest statement: The authors have no proprietary, financial, professional or other personal interest of any nature or kind in any product, service and/or company that could be construed as influencing the position presented in, or the review of this manuscript.

Références

Am J Gastroenterol. 2008 May;103(5):1122-30
pubmed: 18445096
Am J Gastroenterol. 2002 Jul;97(7):1696-700
pubmed: 12135020
Gastrointest Endosc. 2006 Jun;63(7):894-909
pubmed: 16733101
Gastroenterology. 2014 Oct;147(4):903-24
pubmed: 25239068
Endoscopy. 2019 Jan;51(1):60-72
pubmed: 30025414
Gastrointest Endosc. 2005 Mar;61(3):378-84
pubmed: 15758907
Gastrointest Endosc. 2018 Mar;87(3):677-687.e3
pubmed: 28803744
Endoscopy. 2019 Jan;51(1):73-84
pubmed: 30025415
Clin Gastroenterol Hepatol. 2016 Aug;14(8):1155-62
pubmed: 27060426
Ann Intern Med. 2009 Jan 6;150(1):1-8
pubmed: 19075198
PLoS One. 2016 Jun 03;11(6):e0154149
pubmed: 27257916
Gastrointest Endosc. 2014 Mar;79(3):448-54
pubmed: 24246797
Int J Colorectal Dis. 2013 Jan;28(1):73-81
pubmed: 22885884
Frontline Gastroenterol. 2013 Apr;4(2):112-119
pubmed: 28839711
Gut. 2012 Jul;61(7):1050-7
pubmed: 21940723
N Engl J Med. 2014 Aug 28;371(9):799-807
pubmed: 25162886
Endoscopy. 2019 Aug;51(8):775-794
pubmed: 31295746

Auteurs

Marcello Maida (M)

Gastroenterology and Endoscopy Unit, S. Elia-Raimondi Hospital, Caltanissetta 93100, Italy. marcello.maida@hotmail.it.

Emanuele Sinagra (E)

Gastroenterology and Endoscopy Unit, Istituto San Raffaele Giglio, Cefalù 90015, Italy.

Gaetano Cristian Morreale (GC)

Gastroenterology and Endoscopy Unit, S. Elia-Raimondi Hospital, Caltanissetta 93100, Italy.

Sandro Sferrazza (S)

Gastroenterology and Endoscopy Unit, Santa Chiara Hospital, Trento 38014, Italy.

Giuseppe Scalisi (G)

Gastroenterology Unit, ARNAS Garibaldi, Catania 95100, Italy.

Dario Schillaci (D)

Gastroenterology Unit, Basarocco Hospital, Niscemi 93015, Caltanissetta, Italy.

Marco Ventimiglia (M)

Department of Internal Medicine, Villa Sofia-Cervello Hospital, Palermo 90100, Italy.

Fabio Salvatore Macaluso (FS)

Department of Internal Medicine, Villa Sofia-Cervello Hospital, Palermo 90100, Italy.

Giovanni Vettori (G)

Gastroenterology and Endoscopy Unit, Santa Chiara Hospital, Trento 38014, Italy.

Giuseppe Conoscenti (G)

Gastroenterology and Endoscopy Unit, Istituto San Raffaele Giglio, Cefalù 90015, Italy.

Concetta Di Bartolo (C)

Gastroenterology Unit, ARNAS Garibaldi, Catania 95100, Italy.

Serena Garufi (S)

Gastroenterology and Endoscopy Unit, S. Elia-Raimondi Hospital, Caltanissetta 93100, Italy.

Domenico Catarella (D)

Gastroenterology Unit, ARNAS Garibaldi, Catania 95100, Italy.

Michele Manganaro (M)

Gastroenterology and Endoscopy Unit, S. Elia-Raimondi Hospital, Caltanissetta 93100, Italy.

Clara Maria Virgilio (CM)

Gastroenterology Unit, ARNAS Garibaldi, Catania 95100, Italy.

Salvatore Camilleri (S)

Gastroenterology and Endoscopy Unit, S. Elia-Raimondi Hospital, Caltanissetta 93100, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH